{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE276nnn/GSE276006/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE276006"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"CD40ag Activated B Cells Elicit Anti-Tumor Immunity [scRNAseq]","description":"We leveraged mouse models of Triple Negative Breast cancer of varying tumor mutation burdens to elucidate ways that direct activation of B cells can illiciate an anti-tumor effect. These syngenic tranplant models were treated with a combination of CD40 agonist immunotherapy or anti-CD19. Primary tumors of both treated and nontreated conditions were profiled by RNA-SEQ. These tumors that have been profiled describe the impact that B cell acitvation has on CD40 agonist immunotherapy treatment and tumor progression.","dates":{"publication":"2026/08/13"},"accession":"GSE276006","cross_references":{"GSM":["GSM8489315","GSM8489314"],"GPL":["21103","30172"],"GSE":["276006"],"taxon":["Mus musculus"]}}